Microbio announced today a new distribution partnership with Shiva Scientific, a leading provider of laboratory and molecular diagnostic solutions in India. This agreement marks a key milestone in Microbio’s mission to broaden the availability of its InfectID™-BSI test, a groundbreaking tool for rapid pathogen detection in bloodstream infections, including sepsis.
InfectID™-BSI is an innovative molecular diagnostic test capable of identifying 26 pathogens associated with sepsis, enabling clinicians to administer targeted treatment in less than three hours. The assay works by targeting the pathogen’s DNA ‘fingerprint’. Utilizing melt curve technology, InfectID™-BSI rapidly identifies sepsis-causing pathogens directly from blood samples. Without the need for enrichment or culture, this CE-marked & Indian CDSCO approved product, offers a powerful tool to improve patient outcomes through quicker and more
accurate treatment, potentially improving outcomes in critical care scenarios and aiding in the fight against sepsis – a condition responsible for millions of deaths worldwide annually.
Through this agreement, Shiva Scientific will act as Microbio’s exclusive distribution partner across India, bringing InfectID™-BSI to hospitals and labs across the country. Shiva Scientific’s established presence and dedication to advancing diagnostic solutions align closely with Microbio’s vision to enhance patient care through pioneering diagnostic tools.
“We are delighted to join forces with Shiva Scientific to expand our reach in Asia,” said Johan Vanderhoeven, Chief Commercial Officer at Microbio. “Shiva Scientific’s experience and insight into the Indian healthcare market make them an ideal partner to help us introduce InfectID™-BSI to a wider audience and improve the diagnosis and treatment of serious infections.”
“We are thrilled to partner with Microbio Ltd. to bring fast and advanced sepsis pathogen identification solutions to the Indian healthcare providers” said Dr. Dinesh C. Upadhyay, Managing Director at Shiva Scientific. “This collaboration aligns with our commitment to providing cutting-edge diagnostic tools that support timely and accurate patient care. Together, with this partnership we look forward to empowering healthcare providers with technology that can significantly impact patient outcomes in critical situations and save millions of lives.”
This new agreement with Shiva Scientific is part of Microbio’s strategic expansion across global markets, reaffirming its
commitment to delivering innovative diagnostic solutions that meet the diverse needs of healthcare providers around the world.